Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2 vs 6 Hour Oxaliplatin Infusion in GI Cancers
NCT03800693Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Mar 2019
- Primary completion
- Aug 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin in gastrointestinal cancer (2 arms), sponsored by Emory University. Primary endpoint: Severity of sensory neuropathy as measured by EORTC CIPN-20 score. Started Mar 2019; status: recruiting.
02
Drugs
oxaliplatin
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT03800693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800693.